144 related articles for article (PubMed ID: 20130422)
1. Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.
Tiersten AD; Moon J; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Oncology; 2009; 77(6):395-9. PubMed ID: 20130422
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
[TBL] [Abstract][Full Text] [Related]
4. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
5. Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
Craig AD; Garcia E; Peters PN; Chen LM; Chapman JS
Future Oncol; 2021 Dec; 17(34):4687-4696. PubMed ID: 34435878
[TBL] [Abstract][Full Text] [Related]
6. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
7. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
8. Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; Albert-Marí A; Borrell-García C; Melián-Sosa M; Salvador-Coloma C; Santaballa-Bertrán A; Poveda-Andrés JL
J Oncol Pharm Pract; 2021 Mar; 27(2):268-278. PubMed ID: 32279599
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
14. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
[TBL] [Abstract][Full Text] [Related]
15. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
18. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
19. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
